Angiotensin II type 1-receptor activating antibodies in renal-allograft rejection. - Test2 - elhamkhani - TriplyDB

Angiotensin II type 1-receptor activating antibodies in renal-allograft rejection.

Angiotensin II type 1-receptor activating antibodies in renal-allograft rejection.

http://www.wikidata.org/entity/Q45259438

about

Angiotensin receptors, autoimmunity, and preeclampsia Recent advances in central cardiovascular control: sex, ROS, gas and inflammation Preeclampsia: long-term consequences for vascular health The use of novel diagnostics to individualize immunosuppression following transplantation Vascular endothelium as a target of immune response in renal transplant rejection Angiotensin receptor agonistic autoantibodies and hypertension: preeclampsia and beyond Effector mechanisms of rejection Unraveling the Role of Allo-Antibodies and Transplant Injury Antibody Subclass Repertoire and Graft Outcome Following Solid Organ Transplantation Immune-mediated vascular injury and dysfunction in transplant arteriosclerosis Immunity in arterial hypertension: associations or causalities?HIF-1α signaling by airway epithelial cell K-α1-tubulin: role in fibrosis and chronic rejection of human lung allografts Potential relevance of alpha(1)-adrenergic receptor autoantibodies in refractory hypertension De novo production of K-alpha1 tubulin-specific antibodies: role in chronic lung allograft rejection.Autoimmune mechanisms activating the angiotensin AT1 receptor in 'primary' aldosteronism.Endothelial dysfunction induced by antibodies against angiotensin AT1 receptor in immunized rats Hypertension in the Pediatric Kidney Transplant Recipient B-cell immunity in the context of T-cell tolerance after combined kidney and bone marrow transplantation in humans.Mechanisms of Autoantibody-Induced Pathology.Angiotensin receptor type 1 and endothelin receptor type A on immune cells mediate migration and the expression of IL-8 and CCL18 when stimulated by autoantibodies from systemic sclerosis patients Ligand-specific conformation of extracellular loop-2 in the angiotensin II type 1 receptor.Pretransplant IgG reactivity to apoptotic cells correlates with late kidney allograft loss.Lipid raft facilitated ligation of K-alpha1-tubulin by specific antibodies on epithelial cells: Role in pathogenesis of chronic rejection following human lung transplantation.The generation and maintenance of serum alloantibody.Non-MHC antigenic targets of the humoral immune response in transplantation Preeclampsia from a renal point of view: Insides into disease models, biomarkers and therapy.Increase of angiotensin II type 1 receptor auto-antibodies in Huntington's disease.Antiperlecan antibodies are novel accelerators of immune-mediated vascular injury.The immunological basis of hypertension Role of angiotensin II type I receptor agonistic autoantibodies (AT1-AA) in preeclampsia.Diagnosis and management of antibody-mediated rejection: current status and novel approaches.Alloimmunity-induced autoimmunity as a potential mechanism in the pathogenesis of chronic rejection of human lung allografts.Agonistic antibody to angiotensin II type 1 receptor accelerates atherosclerosis in ApoE-/- mice.Antibodies reactive to non-HLA antigens in transplant glomerulopathy Perindopril treatment promote left ventricle remodeling in patients with heart failure screened positive for autoantibodies against angiotensin II type 1 receptor Hypertension in response to placental ischemia during pregnancy: role of B lymphocytes.Anticardiac myosin immunity and chronic allograft vasculopathy in heart transplant recipients.Autoimmunity: an underlying factor in the pathogenesis of hypertension.Emerging role of B cells in chronic allograft dysfunction.Late kidney allograft loss: what we know about it, and what we can do about it

P2860

Q24605647-876280F5-0B10-4C31-96DD-6252137B73D6 Q26752442-05792886-5BF0-4956-B863-236D1A9D30CF Q26800272-4009867A-B4DD-4FEC-B17D-68377EC2E911 Q26864686-524E2CB7-0682-4046-B316-1D98DA6EAAB9 Q27024077-D8C0B7FA-D8F9-452D-95CD-45D20A9B2DF3 Q27027039-F5AA2F17-1EAD-4014-ADD3-F7887890CCBC Q27027082-96534364-1FBA-4F47-913D-C6036D3B7EF6 Q28069336-39EAAC32-6083-451B-BB17-05B05BCB816A Q28076193-CAE84D1D-E303-456C-AB40-22E588AF66BB Q28084366-20F967FC-57AB-4185-9956-CF910D937B71 Q28087302-DEF2C529-DD49-4D29-B2D4-CC4B9EBFA0B3 Q28395914-354DA422-6FFE-4156-94DB-0BDB9AED5A84 Q28575913-04548979-73FD-4239-8344-CBE646256E2F Q33551885-F3E623DA-645F-4DBE-9E6E-20BA1B5E3AAB Q33568986-75212EAB-A8BD-4F04-BB58-D3333F1D1908 Q33577570-C8EE6083-C139-4C4F-9769-04EB761F45D6 Q33619380-96776758-198D-4A7D-8FAB-09937B3D2E0F Q33723769-6FD0F3E5-4F07-43CE-903E-F0E5836A666A Q33740580-749D2B5A-3E45-432D-B1FB-45FDBDAFB13D Q33765684-91AD2DCF-37E6-4100-8485-77CF8A9CF761 Q33855316-BD4FCFB0-93BB-4BDB-9E5F-88698D917D9E Q33998148-0BE12E2A-5FCE-4F7C-900F-682383861610 Q34079646-67188178-1E2E-4C88-800D-0206753365C5 Q34106158-3E9A68C8-01B4-4404-BC34-4985DAE2C01E Q34259047-5BF0C763-781C-4F89-8A04-5C008FFB0D91 Q34453242-A713721A-835C-4F2B-80FE-31E06CA3C81F Q34581918-1D6B9B28-881E-46D5-A950-86F6D63FD0E6 Q34595998-3880C2A0-290E-452D-8D6B-A51DF991B810 Q34683745-B053BFCF-A6E5-443A-B9AC-3A21AFD48A7E Q34785813-EC254040-5AC9-4DB9-9C7A-A25020A11A65 Q34841849-95C37EE0-ED3A-468B-BEFF-2D7BE79442AE Q34970022-70345797-A8C9-46F5-A8DB-DC1E1C807430 Q34978758-780DB9F1-0E3B-4BBB-85F8-D889D1FB8307 Q35012455-60824606-F20F-4886-810E-84CCF396351C Q35029497-D35C1976-EF63-4220-9707-61B46EF18B75 Q35029700-AFEDCD69-5087-440E-B93F-6DA3CD117F78 Q35091339-82E99027-0586-450C-B1C9-58A4C2B8EADC Q35116086-E76AA4FF-5489-4D7D-9CC9-0A486541804E Q35124576-2EDA6950-27AA-4F6F-A14F-C8B2C5640A69 Q35153318-1981241B-A216-4313-96DD-55B43DAE949C

P2860

Angiotensin II type 1-receptor activating antibodies in renal-allograft rejection.

http://www.wikidata.org/entity/Q45259438

description

2005 nî lūn-bûn

@nan

2005年の論文

@ja

2005年学术文章

@wuu

2005年学术文章

@zh

2005年学术文章

@zh-cn

2005年学术文章

@zh-hans

2005年学术文章

@zh-my

2005年学术文章

@zh-sg

2005年學術文章

@yue

2005年學術文章

@zh-hant

name

Angiotensin II type 1-receptor activating antibodies in renal-allograft rejection.

@en

Angiotensin II type 1-receptor activating antibodies in renal-allograft rejection.

@nl

type

label

Angiotensin II type 1-receptor activating antibodies in renal-allograft rejection.

@en

Angiotensin II type 1-receptor activating antibodies in renal-allograft rejection.

@nl

prefLabel

Angiotensin II type 1-receptor activating antibodies in renal-allograft rejection.

@en

Angiotensin II type 1-receptor activating antibodies in renal-allograft rejection.

@nl

P1433

Q45259438-D3A0144B-A952-47CA-B3A3-7CCF0FD6CB2D

P1476

Q45259438-8B6ECF1B-CF6D-4425-AAD4-D338DE2B92B6

P2093

Q45259438-03E3CCB9-1B72-4858-B2DF-E2C6439E3806

Q45259438-0EFE4104-4F7A-4D97-B287-04F88709CF31

Q45259438-14EDEA09-663F-4886-8EDB-4028044240FD

Q45259438-398CE7F6-F095-49D3-AEFF-FC730FCE089F

Q45259438-4B725A6A-4E37-44E3-83EF-6DC932213016

Q45259438-62ED5BB5-EE48-48B7-8452-7FE073886D74

Q45259438-6CCD7A97-279E-416F-8994-0F1781F46CEA

Q45259438-6D1EC2AB-2758-4ACB-8FAF-08D8D7C154A8

Q45259438-7F58DD6B-65C1-4CEE-A750-65E4D4452D44

Q45259438-94555DE9-E949-48F9-A6CC-241492640895

P304

Q45259438-E6B896E6-F27F-4969-9DAF-C91507D3F9BC

P31

Q45259438-50D60531-7B42-4792-BB1D-1F37F93B045C

P356

Q45259438-06BC7DAB-5254-4C5E-8298-3960990BC76A

P407

Q45259438-C93A81D6-5ABA-4172-AB88-65110BC40046

P433

Q45259438-082B32C7-F834-4E79-9341-755A03824091

P478

Q45259438-56FE5314-62C8-4A30-8C55-6BF484B200E8

P50

Q45259438-15A91C85-D000-484C-ABC1-5A065D2F26A1

Q45259438-7E08D316-2915-4F18-A2E2-DE751204E771

Q45259438-9074A153-2736-4143-ABD3-9B37D8B8E954

Q45259438-95E9D28E-B6EA-46F3-8963-4F2A7A66E435

Q45259438-9BF63958-6BC4-43E7-90C7-DA770A2A8DE9

P577

Q45259438-F4198F25-CD7C-4C8D-8DBC-A92FB1068477

P698

Q45259438-309AB17E-2ED6-4BAD-9524-8D49EAAA1DCE

P921

Q45259438-13370C2A-F0F1-4EC4-964D-C76A8F9CAF1D

Q45259438-98964CE4-BE81-4E40-AE67-86B110AFB1EA

Q45259438-DFD25A0A-8368-4D38-B5C9-F7CCD0CAB0F8

P356

P1433

The New England Journal of Medicine

P1476

Angiotensin II type 1-receptor activating antibodies in renal-allograft rejection.

@en

P2093

Birgit Rudolph

http://www.w3.org/2001/XMLSchema#string

Constanze Schönemann

http://www.w3.org/2001/XMLSchema#string

Diana Eckert

http://www.w3.org/2001/XMLSchema#string

Dominik N Müller

http://www.w3.org/2001/XMLSchema#string

Duska Dragun

http://www.w3.org/2001/XMLSchema#string

Hans-Hellmut Neumayer

http://www.w3.org/2001/XMLSchema#string

Istvan Mazak

http://www.w3.org/2001/XMLSchema#string

Jan Hinrich Bräsen

http://www.w3.org/2001/XMLSchema#string

Johan Hoebeke

http://www.w3.org/2001/XMLSchema#string

Klemens Budde

http://www.w3.org/2001/XMLSchema#string

P304

558-569

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1056/NEJMOA035717

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

352

http://www.w3.org/2001/XMLSchema#string

P50

Friedrich C. Luft

Ulrich Kintscher

P577

2005-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

15703421

http://www.w3.org/2001/XMLSchema#string

P921